View the third webinar in spring series: http://bit.ly/apr-11-webinar, recorded on April 11.
In just about two weeks, the U.S. Food and Drug Administration (FDA) will host a two-day workshop on drug development for CFS and ME. The FDA’s review process is designed to test potential treatments for both safety and effectiveness for the condition they aim to treat. What does the phrase “safe and effective treatment” really mean?
We break down each word in that phrase to help participants understand how treatment candidates are reviewed and how patient experience in clinical trials affects the approval process.
Date/Time: April 11 at 1 p.m. EDT
Speakers: Kim McCleary, President & CEO, The CFIDS Association of America
Host: Suzanne Vernon, PhD, Scientific Director, The CFIDS Association of America
- (FDA materials)
- (FDA materials)
- “Who Pays for Treatments and Cures?” (video from FasterCures’ Celebration of Science)
The first two programs in our spring webinar series provide helpful background information for this topic. Recordings are archived on the Association’s SolveCFS YouTube channel:
- (March 28, 2013, featuring Kristin Schneeman of FasterCures)
- “Finding Your Strongest Voice for Public Testimony” (April 4, 2013, featuring Leigh Reynolds and Kim McCleary of the CFIDS Association of America)
If you haven’t already done so, please complete our Patient-Focused Survey. We’re collecting information about symptoms, impact of ME/CFS on daily living and treatments. This information will be analyzed using tools called Natural Language Processing and Parts of Speech to help us present to FDA and other policymakers a comprehensive and detailed profile of how people living with ME/CFS describe their illness. Your input is vital. Thanks to the 988 people who have already taken time to share their experiences.
We look forward to your participation in the upcoming webinar and survey. Thank you for your continued support of the CFIDS Association of America. You’re at the center of everything we do!